Graham, David Y. http://orcid.org/0000-0002-6908-8317
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK56338)
Article History
Received: 29 November 2022
Accepted: 14 February 2023
First Online: 1 March 2023
Declarations
:
: Dr. Graham is a consultant for RedHill Biopharma and Phathom Pharmaceuticals regarding novel <i>H. pylori</i> therapies and has received research support for culture of <i>Helicobacter pylori</i>. He is also a consultant with Janssen Research & Development regarding potential gastrointestinal effects of drugs under development and has collaborated on research projects with American Molecular regarding molecular diagnostics for <i>H. pylori</i>.